Physician profile
Michael Lunsford
NPI 1962484311
$5,383.74
in general payments reported to CMS, 2019-2025
29 companies · $676 in 2025
The $676 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $891 · 2021: $693 · 2022: $577 · 2023: $977 · 2024: $662 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $708.61 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $613.04 | 2022-2025 | Azstarys |
| Pfizer INC. | $495.33 | 2019-2024 | |
| Ironshore Pharmaceuticals INC. | $470.69 | 2019-2024 | Jornay Pm |
| Novo Nordisk INC | $411.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $364.98 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Sobi, INC | $333.26 | 2019-2024 | |
| Tris Pharma INC | $264.23 | 2020-2025 | Dyanavel Xr |
| Sanofi Pasteur INC. | $256.21 | 2020-2025 | |
| Abbvie INC. | $247.38 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $195.06 | 2021-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $164.31 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $156.11 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $118.00 | 2019-2025 | Breztri |
| Sanofi-Aventis U.S. LLC | $107.75 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $76.95 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $70.30 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $46.92 | 2021-2022 | |
| Seqirus USA INC | $44.58 | 2022-2025 | Flucelvax, Fluad Quadrivalent, Flucelvax Quadrivalent |
| Neos Therapeutics, LP | $40.33 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.11 | 2021 | |
| Shire North American Group INC | $29.52 | 2019 | |
| Genentech USA, INC. | $28.34 | 2019-2020 | |
| Adlon Therapeutics L.P. | $25.94 | 2019-2020 | |
| Dexcom, INC. | $18.62 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.45 | 2020 | |
| Abbott Laboratories | $17.32 | 2021 | |
| Exact Sciences Corporation | $13.66 | 2023 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $13.62 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lunsford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.